6:16 PM
 | 
Dec 04, 2012
 |  BC Extra  |  Company News

Wilex reduces headcount after Rencarex miss

Wilex AG (Xetra:WL6) will reduce headcount by up to 19 to about 110 after reporting in October that Rencarex girentuximab missed the primary endpoint in the Phase III ARISER trial to treat clear cell renal cell carcinoma (RCC). Wilex said the cuts will come only from its Munich, Germany...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >